Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Cisco Systems

Chevron

Dow Inc

Coca-Cola

Merck

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walgreens

The Dogs of the Dow were flea-bitten last year, but this simple dividend-investing strategy will try to return to greatness in 2021.

Dogs of the Dow 2021: 10 Dividend Stocks to Watch

Boeing

Salesforce

Pfizer

Exxon Mobil

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2021 Dogs of the Dow

Teladoc

If you're worried about another market crash, don't pass up these three unstoppable healthcare stocks.

3 No-Brainer Stocks to Buy in Healthcare

SPDR Dow Jones Industrial Average ETF

In the 10 days since we posted our preliminary list of 2021's Dogs of the Dow, more than 23,000 Americans have died from causes related to the COVID-19 pandemic.

2021's Dogs of the Dow

Hopes for growth hinge on continued expansion for new products, as well as a pipeline of drugs in clinical trials.

Amgen's Competition Heated Up in 2020. What's Ahead for the Stock.

Amgen has seen strong revenue and earnings growth, as supported by its strong stable of drugs. It also has a fast-growing biosimilar practice, and a promising pipeline.

Amgen: Now Is A Great Time To Buy This Cash Cow

Atmos Energy

Bristol-Myers

General Dynamics

Lockheed Martin

Pinnacle West Capital

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of dividend growth stocks in Dividend Radar and present the 10 top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to get quality scores and sort them in descending order, breaking ties with additional metrics.

10 Dividend Growth Stocks For December 2020

AstraZeneca

Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.

Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal

The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe

THOUSAND OAKS, Calif. and MELBOURNE, Australia, Dec. 22, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies have entered into a license agreement for AMG 634, a...

Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health

THOUSAND OAKS, Calif., Dec. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with...

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

ABM Industries

Acme United

Balchem

Franklin Resources

City Hld

Ensign Group

Eli Lilly

Washington Trust Bancorp

This weekly article series covers dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Changes: December 12-18, 2020

In terms of its payouts to shareholders, drugmaker Amgen has better stats than the tech powerhouse.

Forget Apple: Here's a Better Dividend Growth Stock

Darden Restaurants

Dividend increases, which were very rare early in the pandemic as plenty of firms cut or suspended their payouts, have become more frequent as 2020 has gone along.

Eli Lilly, Amgen, and 2 Other Companies That Raised Their Dividends This Week

Broadcom

This is an exciting time for dividend growth investors as it seems companies of all sizes and industries are announcing dividend increases. We will highlight three large companies that have provided their shareholders with at least a 10% dividend increase in recent weeks.

3 Stocks Delivering Over 10% Dividend Increases

CAMBRIDGE, Mass., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that Octagon Therapeutics and Seranova Bio have each won an Amgen Golden Ticket to LabCentral, Cambridge's premier launchpad for high-potential life sciences and biotech start-ups. The two...

Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral

THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL),...

FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)

The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer

Home Depot

Visa

And their dividend payments could continue to climb higher.

3 Dividend Stocks That Have Doubled Their Payouts in 5 Years

THOUSAND OAKS, Calif., Dec. 16, 2020 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN) today announced its intention to transfer the securities exchange listing for its 1.250% Senior Notes due 2022 and 2.00% Senior Notes due 2026 (the "Debt Securities") from the New York Stock Exchange to the...

Amgen To Transfer Listing Of Debt Securities To Nasdaq

THOUSAND OAKS, Calif., Dec. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the first quarter of 2021. The dividend will be paid on March 8, 2021, to all stockholders of record as of the close of business on...

Amgen Announces 10% Increase In 2021 First Quarter Dividend

THOUSAND OAKS, Calif., Dec. 16, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an investigational KRASG12C inhibitor for the treatment of patients with KRAS G12C-mutated...

Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation

I run my KISS Portfolio screen each month to look for buying opportunities. I present here the stocks that passed the KISS screen this month.

Undervalued Dividend Growth Stocks: December 2020

Apple

Microsoft

Walmart

For those who are put off by the extreme enthusiasm of this bull market, the usually reliable Dow Jones stocks offer much-needed balance. Here are seven to consider.

The 7 Best Dow Jones Stocks to Buy Now As You Ready for the Coming Year

Amgen (AMGN) closed at $227.40 in the latest trading session, marking a -0.33% move from the prior day.

News for Amgen Stock (AMGN)